Clovis Oncology, Inc. was a big mover last session, as its shares rose a little over 15% on the day. The move came after the company disclosed in a SEC filing that the FDA is not planning an advisory committee meeting to discuss the company's New Drug Application, or NDA, for rucaparib. This led to far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up 69.24% in the past one-month time frame.

Over the last 30 days, the company witnessed one negative estimate revision while the Zacks Consensus Estimate moved higher, suggesting more solid trading ahead. So make sure to keep an eye on this stock going forward to see if yesterday’s jump can turn into more strength down the road.

Clovis Oncology currently carries a Zacks Rank #2 (Buy) while its Earnings ESP is 0.00%.

CLOVIS ONCOLOGY Price

 

CLOVIS ONCOLOGY Price | CLOVIS ONCOLOGY Quote

A better-ranked stock in the med-biomed/gene space is Geron Corporation (GERN Quick QuoteGERN - Free Report) , which sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is CLVS going up? Or down? Predict to see what others think: Up or Down

Confidential from Zacks

Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>